Algernon Logo 1.png
Algernon Announces Warrant Extension
04 nov. 2024 18h30 HE | Algernon Pharmaceuticals Inc.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Closing of Private Placement
20 août 2024 07h00 HE | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Increase to Private Placement
13 août 2024 07h18 HE | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Private Placement
07 août 2024 17h02 HE | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Closing of Private Placement
02 août 2024 07h00 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Increase to Private Placement
31 juil. 2024 07h00 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
16 juil. 2024 08h00 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Private Placement
11 juil. 2024 16h15 HE | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
21 mai 2024 07h00 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon Logo 1.png
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
24 avr. 2024 07h47 HE | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...